CatalYm GmbH
CatalYm GmbH is a biopharmaceutical company located in Planegg, Bayern, Germany. Founded in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg, the company focuses on developing innovative cancer immunotherapies. Its primary product is visugromab, a monoclonal antibody targeting Growth-and-Differentiation Factor 15 (GDF-15). This therapy aims to overcome resistance to cancer treatments and enhance the effectiveness of existing immunotherapies, particularly for patients with high unmet medical needs. The leadership team includes CEO Scott Clarke, who has extensive experience in the biopharmaceutical industry, and CFO Anne Burger, known for her expertise in financial operations and fundraising. CatalYm is supported by several international venture capital investors and receives backing from the European Investment Fund. The company's research emphasizes understanding GDF-15's role in immunosuppression within tumors, aiming to provide new treatment options for patients facing limited therapeutic choices.
Work at CatalYm GmbH in HR or recruiting? Claim this page
Headcount trend
CatalYm GmbH went from 0 employees in Jul 2023 to 3 in Jun 2025. Jan to Jun 2025: 2 people joined, 0 left.
Headcount data through Jun 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Jul 2024 | Series D | $150M | 8 | |
| Nov 2022 | Series C | $49M | 8 | |
| Nov 2020 | Series B | $59.3M | 5 | |
| Nov 2020 | Debt Financing | – | 5 | |
| Oct 2018 | Series A | – | 2 |
Org structure
Headcount by department
Peer reviews
Worked with someone at CatalYm GmbH?
Anonymous peer reviews on OffTheRecord
Similar companies
CatalYm GmbH FAQ
How many employees does CatalYm GmbH have?
CatalYm GmbH has about 3 employees, up 50% over the 3 months to Jun 2025.
What is CatalYm GmbH's revenue per employee?
CatalYm GmbH makes about $667K in revenue per employee, based on $2M annual revenue and 3 employees.
How much funding has CatalYm GmbH raised?
CatalYm GmbH has raised $258.31M in total funding; its latest round was Series D in Jul 2024.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.